聚乙二醇干扰素α-2b治疗不可切除或复发颅咽管瘤的II期研究
每周皮下注射聚乙二醇干扰素α-2b最多18疗程(108周),耐受良好无4/5级毒性;仅手术组7例中2例(28.6%)部分缓解但仅1例持续超3个月,曾放疗组11例无客观影像学缓解,中位无进展生存期19.5个月。
要点
- 聚乙二醇干扰素α-2b在儿童及年轻成人复发颅咽管瘤中耐受良好,无4/5级毒性。
- 仅手术组部分缓解率28.6%(2/7),但仅1例持续超过3个月。
- 曾放疗组无客观影像学缓解,中位无进展生存期19.5个月。
核心结论
- 聚乙二醇干扰素α-2b替代或序贯放疗在儿童及年轻成人复发颅咽管瘤中耐受良好,客观缓解有限但无进展生存期结果令人鼓舞,值得进一步研究。
研究设计与样本
- 儿童脑肿瘤联盟(PBTC)开展的多中心II期研究(PBTC-039),入组19例不可切除或复发颅咽管瘤儿童及年轻成人,中位年龄13.1岁(范围2-25岁)。
- 患者分两层:既往仅手术治疗(层1)或曾接受放疗(层2)。
主要发现
- 18例合格患者接受每周皮下注射聚乙二醇干扰素α-2b,最多18疗程(108周)。
- 治疗耐受良好,无4级或5级毒性。
- 层1可评估7例中2例(28.6%)达部分缓解,但仅1例缓解持续超过3个月。
- 层2的11例患者均无客观影像学缓解,中位无进展生存期为19.5个月。
临床怎么用
- 对于不可切除或复发颅咽管瘤儿童及年轻成人,聚乙二醇干扰素α-2b可作为替代或序贯放疗的耐受性良好的治疗选择。
- 治疗前应告知患者及家属客观影像学缓解率有限,但无进展生存期可能获益。
局限性
- 样本量小(共19例入组,18例治疗),分层后各组例数更少。
- 层1部分缓解仅1例持续超过3个月,客观缓解有限。
- 层2无客观影像学缓解,结果需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Craniopharyngiomas account for approximately 1.2-4% of all CNS tumors. They are typically treated with a combination of surgical resection and focal radiotherapy. Unfortunately, treatment can lead to permanent deleterious effects on behavior, learning, and endocrine function. METHODS: The Pediatric Brain Tumor Consortium performed a multicenter phase 2 study in children and young adults with unresectable or recurrent craniopharyngioma (PBTC-039). Between December 2013 and November 2017, nineteen patients (median age at enrollment, 13.1 y; range, 2-25 y) were enrolled in one of 2 strata: patients previously treated with surgery alone (stratum 1) or who received radiation (stratum 2). RESULTS: Eighteen eligible patients (8 male, 10 female) were treated with weekly subcutaneous pegylated interferon alpha-2b for up to 18 courses (108 wk). Therapy was well tolerated with no grade 4 or 5 toxicities. 2 of the 7 eligible patients (28.6%) in stratum 1 had a partial response, but only one response was sustained for more than 3 months. None of the 11 stratum 2 patients had an objective radiographic response, although median progression-free survival was 19.5 months. CONCLUSIONS: Pegylated interferon alpha-2b treatment, in lieu of or following radiotherapy, was well tolerated in children and young adults with recurrent craniopharyngiomas. Although objective responses were limited, progression-free survival results are encouraging, warranting further studies.
引用
- Goldman S, Pollack IF, Jakacki RI, et al. Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 2020. PMID: 32393959. doi:10.1093/neuonc/noaa119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。